Educational Background: BS from University of Michigan, MS from Wayne State University, and MD from Wayne State University
Research Interests: My primary interests both clinically and investigational is in gastrointestinal and breast malignancies. As a young investigator I’m excited to offer treatment opportunities through clinical trials for my patients. I am also involved in developing quality improvement projects to provide the best oncology care for our patients.
Fun Facts: I enjoy cooking/grilling.
I enjoy hands-on projects including fixing cars and working in the yard.
May 7, 2017: The skin protects against heat, sunlight, injury, and infection. Skin also helps control body temperature and stores water and fat. Skin cancer is the most common type of cancer. It usually forms in skin that has been exposed to sunlight, but can occur anywhere on the body. Skin has several layers. According to the National Cancer Institute, skin cancer begins in the epidermis (outer layer), which is made up of squamous cells, basal cells, and melanocytes. You can learn more about skin cancer, including melanoma, from the National Cancer Institute. May is Skin Cancer Detection and Prevention Month. This month, the members of the Big Ten Cancer Research... Read More
Apr. 21, 2017: Innovative therapies with hard-hitting impact; that must have been the game plan developed in the last huddle of the Big Ten Cancer Centers! This month's Across the Consortium is your instant replay of the amazing achievements making headlines across the country, from dynamic new treatments to prototype diagnostics for early detection. Be inspired as you catch all the action. Read More
April 19, 2017:The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2017. Read More
April 1, 2017:Investigator SpotlightLawrence Feldman, MD Educational Background: MD from University of Michigan Research Interests: Dr. Feldman’s research interests lie in finding the optimal treatments to improve the response, survival rates, and quality of life in the treatment of lung and head and neck cancers. He is the UIC Principal Investigator on several studies that test the role of targeted agents in the treatment of lung and head and neck cancer. He is also interested in the application of large databases to answer critical clinical questions in the management of these malignancies. Fun Facts: He is a "gym rat" and loves the game of basketball. His father was a family practice physician and used to make house calls. He and his wife have 2 grown sons and 2... Read More
March 19, 2017: Each month, the Big Ten Cancer Research Consortium highlights advances in research and treatment led by our member institutions. Get up to date on the latest discoveries and breakthroughs from Across the Consortium!Read More
March 11, 2017: March is the time to take stock of the number two ranking cause of cancer deaths in the United States: colorectal cancer (cancer of the colon or rectum). Since this time last year, it is estimated that 140,000 Americans were diagnosed with colorectal cancer, and more than 50,000 people died from it. During Colorectal Cancer Awareness Month, researchers, clinicians, survivors, and patients unite with the common purpose of discovering hope for those facing this cancer. Read More
March 3, 2017: Triple negative breast cancer (TNBC) represents a relatively small proportion — 15 percent — of all breast cancers. Yet a great deal of attention has been given to TNBC in recent years. While targeted therapies have been developed for breast cancers expressing estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, advances in TNBC have been hampered by a lack of identified targets for the disease. As a result, the only approved treatment for TNBC remains chemotherapy. Recent discoveries, however, have identified several molecular subtypes of TNBC, and researchers are now developing clinical trials to explore potential ways to treat these subtypes. A new Big Ten Cancer Research Consortium study, led by Ruth O’Regan, MD (pictured), of the University of... Read More
March 1, 2017:Investigator Spotlight Mark Stein, MD Educational Background: BS, Yale; MD, New York Medical College; Internal Medicine, Albert Einstein; Fellowship in Oncology Hematology, Mount Sinai School of Medicine Rutgers Cancer Institute of New Jersey. 1/13/17 Photo by John O'Boyle Research Interests: I am interested in developing novel therapies for the treatment of genitourinary malignancies. The potential benefit of immunotherapy for the treatment of prostate cancer is still poorly understood. Through collaboration’s with my colleagues at Rutgers, pharmaceutical companies (some of which are even located in New Jersey) and other members of the Big Ten, it is my hope that we will be able to utilize immunotherapy earlier in the course of treatment of prostate cancer and... Read More
Feb. 21, 2017: For more than 25 years, Lawrence Feldman, MD, has been researching and treating patients with lung and head and neck cancers. In all those years, there have been few times that rival the optimism he feels when he considers the recent discoveries and advances in cancer immunotherapy. “Over the last couple of years, immuno-oncology has been very successful in both lung and head and neck cancer. It’s been a very exciting area,” Dr. Feldman, a researcher at the University of Illinois at Chicago, said. The approval of the PD-1 checkpoint inhibitor pembrolizumab (Keytruda®) by the U.S. Food and Drug Administration, first in advanced melanoma, and more recently in advanced non-small cell lung cancer and head and neck cancer, has accelerated progress in the fight against cancer. Pembrolizumab... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube